Delayed BCG vaccination-time to take a shot

Journal of Infectious Diseases

Volumn 211, Issue 3, 2015, Pages 335-337

  Kay, Alexander W ^a   Blish, Catherine A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV exposed BCG; HIV infected; infant; T cell; tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 17;

ATYPICAL MYCOBACTERIUM; BCG VACCINATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; HIGH RISK INFANT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; INCIDENCE; LYMPHOCYTE FUNCTION; MILIARY TUBERCULOSIS; NOTE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; THERAPY DELAY; TREATMENT OUTCOME; TUBERCULOUS MENINGITIS; CD8+ T LYMPHOCYTE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE;

BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE;

EID: 84922496412     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu435     Document Type: Note

References (35)

1. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-80.
2. Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014; 58:470-80.
3. Ndirangu J, Bärnighausen T, Tanser F, Tint K, Newell M-L. Levels of childhood vaccination coverage and the impact of maternal HIV status on child vaccination status in rural KwaZulu-Natal, South Africa∗. Trop Med Int Health 2009; 14:1383-93.
4. Hesseling AC. Disseminated bacille Calm-ette-Guerin disease in HIV-infected South African infants. Bull World Health Organ 2009; 87:505-11.
5. Hesseling AC, Caldwell J, Cotton MF, et al. BCG vaccination in South African HIV-exposed infants-risks and benefits. S Afr Med J 2009; 99:88-91.
6. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007; 25:14-8.
7. Hesseling AC, Cotton MF, Jennings T, et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis 2009; 48:108-14.
8. World Health Organization. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007; 82:193.
9. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. Geneva: World Health Organization, 2014.
10. Mansoor N, Scriba TJ, de Kock M, et al. HIV-1 infection in infants severely impairs the immune response induced by bacille Calmette-Guérin vaccine. J Infect Dis 2009; 199:982-90.
11. Rabie H, Violari A, Duong T, et al. Early an-tiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. Int J Tuberc Lung Dis 2011; 15: 1194-200.
12. Cotton MF, Schaaf HS, Lottering G, et al. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis 2008; 12:225-7.
13. Cranmer LM, Kanyugo M, Jonnalagadda SR, et al. High prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants. Pediatr Infect Dis J 2014; 33:401-6.
14. Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011; 365:21-31.
15. Barron P, Pillay Y, Doherty T, et al. Eliminating mother-to-child HIV transmission in South Africa. Bull World Health Organ 2012; 91:70-4.
16. van Schalkwyk C, Mndzebele S, Hlophe T, et al. Outcomes and impact of HIV prevention, ART and TB programs in Swaziland-early evidence from public health triangulation. PLoS One 2013; 8:e69437.
17. Kuhn L, Meddows-Taylor S, Gray G, Tiemes-sen C. Human immunodeficiency virus (HIV)-specific cellular immune responses in newborns exposed to HIV in utero. Clin Infect Dis 2002; 34:267-76.
18. Clerici M, Saresella M, Colombo F, et al. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood 2000; 96:3866-71.
19. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed uninfected children: a growing population with a vulnerable immune system? Clin Exp Immunol 2014; 176:11-22.
20. Shapiro RL, Lockman S, Kim S, et al. Infant morbidity, mortality, and breast milk immunologic profiles among breast-feeding HIV-infected and HIV-uninfected women in Botswana. J Infect Dis 2007; 196:562-9.
21. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J 2007; 26:519-26.
22. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr 2006; 41:504-8.
23. Reikie BA, Naidoo S, Ruck CE, et al. Antibody responses to vaccination among South African HIV-exposed and unexposed uninfected infants during the first 2 years of life. Clin Vaccine Immunol 2013; 20:33-8.
24. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA 2011; 305:576-84.
25. Mazzola TN, da Silva MTN, Abramczuk BM, et al. Impaired bacillus Calmette-Guérin cellular immune response in HIV-exposed, un-infected infants. AIDS 2011; 25:2079-87.
26. Van Rie A, Madhi SA, Heera JR, et al. Gamma interferon production in response to Mycobacterium bovis BCG and Mycobac-terium tuberculosis antigens in infants born to human immunodeficiency virus-infected mothers. Clin Vaccine Immunol 2006; 13: 246-52.
27. Kidzeru EB, Hesseling AC, Passmore J-AS, et al. In-utero exposure to maternal HIV infection alters T-cell immune responses to vaccination in HIV-uninfected infants. AIDS 2014; 28:1421-30.
28. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobac-terium tuberculosis infection. J Exp Med 1993; 178:2249-54.
29. Reed SG, Coler RN, Dalemans W, et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA 2009; 106: 2301-6.
30. Kagina BMN, Abel B, Bowmaker M, et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine 2009; 27:5488-95.
31. Burl S, Adetifa UJ, Cox M, et al. Delaying bacillus Calmette-Guerin vaccination from birth to 4 1/2 months of age reduces postvac-cination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J Immunol 2010; 185: 2620-8.
32. McShane H. Editorial commentary: understanding BCG is the key to improving it. Clin Infect Dis 2014; 58:481-2.
33. Hatherill M, Verver S, Mahomed H, the Taskforce on Clinical Research Issues, Stop TB Partnership Working Group on TB Vaccines. Consensus statement on diagnostic end points for infant tuberculosis vaccine trials. Clin Infect Dis 2012; 54:493-501.
34. Fadnes LT, Jackson D, Engebretsen IM, et al. Vaccination coverage and timeliness in three South African areas: a prospective study. BMC Public Health 2011; 11:404.
35. Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the Expanded Programme on Immunization in Africa: Looking beyond 2015. PLoS Med 2013; 10:e1001405.